Clinical trial B PRECISE 01
Open-label, multicentre, phase Ib dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab +/- fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/1b |
| Academic trial | Non |
| Sponsor | Menarini |
| EudraCT Identifier | 2019-003727-38 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03767335 |
| Inclusion criteria | HER+. Advanced or metastatic with PIK3CA mutation |
| Last update |